<?xml version='1.0' encoding='utf-8'?>
<document id="30593545"><sentence text="In Silico Prediction of the Absorption and Disposition of Cefadroxil in Humans using an Intestinal Permeability Method Scaled from Humanized PepT1 Mice."><entity charOffset="58-68" id="DDI-PubMed.30593545.s1.e0" text="Cefadroxil" /></sentence><sentence text="It is difficult to predict the pharmacokinetics and plasma concentration-time profiles of new chemical entities in humans based on animal data" /><sentence text=" Some pharmacokinetic parameters, such as clearance and volume of distribution, can be scaled allometrically from rodents, mammals, and nonhuman primates with good success" /><sentence text=" However, it is far more challenging to predict the oral pharmacokinetics of experimental drug candidates" /><sentence text=" In the present study, we used in situ estimates of intestinal permeability, obtained in silico and from rat, wild-type (WT), and humanized PepT1 (huPepT1) mice, to predict the systemic exposure of cefadroxil, an orally administered model compound, under a variety of conditions"><entity charOffset="198-208" id="DDI-PubMed.30593545.s5.e0" text="cefadroxil" /></sentence><sentence text=" Using the GastroPlus simulation software program (Simulations Plus, Lancaster, CA), we found that the Cmax and area under the plasma concentration-time curve from time zero to the last measurable concentration of cefadroxil were better predicted using intestinal permeability estimates (both segmental and jejunal) from huPepT1 than from WT mice, and that intestinal permeabilities based on in silico and rat estimates gave worse predictions"><entity charOffset="214-224" id="DDI-PubMed.30593545.s6.e0" text="cefadroxil" /></sentence><sentence text=" We also observed that accurate predictions were possible for cefadroxil during oral dose escalation (i"><entity charOffset="62-72" id="DDI-PubMed.30593545.s7.e0" text="cefadroxil" /></sentence><sentence text="e" /><sentence text=", 5, 15, and 30 mg/kg cefadroxil), a drug-drug interaction study (i"><entity charOffset="22-32" id="DDI-PubMed.30593545.s9.e0" text="cefadroxil" /></sentence><sentence text="e" /><sentence text=", 5 mg/kg oral cefadroxil plus 45 mg/kg oral cephalexin), and an oral multiple dose study [i"><entity charOffset="15-25" id="DDI-PubMed.30593545.s11.e0" text="cefadroxil" /><entity charOffset="45-55" id="DDI-PubMed.30593545.s11.e1" text="cephalexin" /><pair ddi="false" e1="DDI-PubMed.30593545.s11.e0" e2="DDI-PubMed.30593545.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30593545.s11.e0" e2="DDI-PubMed.30593545.s11.e1" /></sentence><sentence text="e" /><sentence text=", 500 mg (6" /><sentence text="7 mg/kg) cefadroxil every 6 hours]"><entity charOffset="9-19" id="DDI-PubMed.30593545.s14.e0" text="cefadroxil" /></sentence><sentence text=" Finally, the greatest amount of cefadroxil was absorbed in duodenal and jejunal segments of the small intestine after a 5 mg/kg oral dose"><entity charOffset="33-43" id="DDI-PubMed.30593545.s15.e0" text="cefadroxil" /></sentence><sentence text=" Thus, by combining a humanized mouse model and in silico software, the present study offers a novel strategy for better translating preclinical pharmacokinetic data to oral drug exposure during first-in-human studies" /><sentence text="" /></document>